Categories Uncategorized

Pure Extract Technologies Inc. Building Presence in Billion-Dollar Mushroom Space

  • “Mushrooms are having a moment,” reports “Forbes” article
  • Sector projected to benefit from both users, investors
  • Pure Extracts Technologies well positioned to partner with organizations eyeing development in both functional, psychedelic products

In what “Forbes” magazine is calling a “moment,” mushrooms are seeing rising popularity as growing numbers of people are interested in using the fungi as well as investing in them. This is great news for companies such as Pure Extract Technologies (“Pure Extracts”), a Canadian plant-based extraction company entering the functional medicinal mushroom space and collaborating in the psychedelic space

“Psychedelics have been a mainstay for a millennia and appreciated in the counter-culture for decades,” observes the article, titled “Psychedelic Events Are Going Mainstream, Where The Much-Maligned Mushroom Industry Focuses On Mental Health” (http://ibn.fm/10yfG). “In 2020, whether consuming, investing, or both, mushrooms are having a moment.” The article, which notes psychedelics’ potential to impact and improve mental health, mentions several upcoming events focused on psychedelic science, innovation and investment opportunities.

These events lend validity to the expanding psychedelic — and functional — mushroom market. Projections call for the global functional mushroom market to grow by a CAGR of 8.04% from 2019 through 2024 (http://ibn.fm/EVDxw), as functional mushrooms are used in a variety of health-care and pharmaceutical products. In addition, the depression medication market, where psychedelic mushrooms are showing strong potential, was projected to grow from $14.5 billion in 2014 to nearly $17.0 billion this year (http://ibn.fm/yoIoo).

Pure Extracts is well positioned to partner with organizations eyeing development in both functional and psychedelic products. The Company’s business model consists of three verticals: in-house brands; toll processing, or offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to sell under their own brands; and white labelling, or supplying products in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.

In addition, Pure Extracts is applying for a Natural Health Products site license from Health Canada, which will enable the production and sales of functional mushroom products in an EU-GMP-compliant environment. Once EU-GMP certified, the products the Company produces in its 10,000-square-foot will qualify for international sales including in Germany where the importation regulations are among the strictest in the world. Finally, Pure Extracts is exploring several joint-development possibilities for Q4 2020 product launches.

Pure Extract Technologies Inc., headquartered in Pemberton British Columbia, is a soon-to-be public, plant-based extraction company with a new vertical in functional mushrooms. The firm is positioned to be a dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extract Technologies are available in the company’s newsroom at http://ibn.fm/Pure

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

4 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

1 month ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

2 months ago